Clinical Report: Outcomes of Medicinal Cannabis Treatment for Fibromyalgia

Overview

This analysis of the UK Medical Cannabis Registry evaluates patient-reported outcomes and adverse events in fibromyalgia patients treated with cannabis-based medicinal products (CBMPs). Findings suggest improvements in pain and quality of life measures over 18 months, with mostly mild to moderate adverse events reported.

Background

Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and cognitive symptoms, affecting approximately 5.4% of adults, predominantly females. Current pharmacological treatments offer limited efficacy and poor tolerability, leading to high discontinuation rates. Cannabis-based medicinal products, containing THC and CBD, have shown potential analgesic and anxiolytic effects, but evidence from randomized controlled trials remains limited and heterogeneous. The UK Medical Cannabis Registry provides real-world data on CBMP use in fibromyalgia patients, addressing gaps in clinical trial data, especially regarding inhaled administration.

Data Highlights

Key Findings

• CBMP treatment was associated with improvements in fibromyalgia-specific and general health PROMs over 18 months.
• Most adverse events reported were mild to moderate in severity.
• Patients included had confirmed fibromyalgia diagnoses and had failed to respond adequately to licensed therapies before CBMP initiation.
• Both oral/sublingual and inhaled CBMP formulations were used, reflecting real-world prescribing patterns.
• The registry data supports the tolerability and potential efficacy of CBMPs in fibromyalgia management.

Clinical Implications

Clinicians may consider CBMPs as an adjunct treatment option for fibromyalgia patients who have inadequate symptom control with standard therapies. The favorable safety profile and improvements in patient-reported outcomes suggest CBMPs could address pain and associated symptoms such as sleep disturbances. However, careful patient selection and monitoring for adverse events remain essential.

Conclusion

This registry-based analysis provides supportive evidence that CBMPs may improve symptoms and quality of life in fibromyalgia patients with a manageable safety profile. Further controlled studies are warranted to confirm these findings and optimize treatment protocols.

References

1. Curaleaf Clinic/UK Medical Cannabis Registry/2023 -- Analysis of Clinical Outcomes from Medicinal Cannabis Treatment for Fibromyalgia